Clario Strengthens Neuroscience Focus Through Acquisition
Clario, a renowned provider of endpoint data solutions for clinical trials, continues to expand its footprint in the neuroscience sector by acquiring NeuroRx. This strategic move reflects Clario's commitment to enhancing its resources in imaging analysis, particularly in the field of multiple sclerosis.
Enhancing Expertise in Imaging Solutions
The acquisition is designed to build upon Clario's established strength in neuroscience. Chris Fikry, M.D., Clario's CEO, expressed enthusiasm for the synergy that NeuroRx's technology and team will bring. He stated, "This strategic acquisition reinforces our strong leadership in imaging and enhances our capabilities in neuroscience, which is critical for advancing medical innovation. We aim to support our customers in developing treatments that truly make a difference."
NeuroRx's Role and Reputation
NeuroRx has gained recognition for its comprehensive suite of imaging services tailored for clinical trials. With years of experience in the approval processes for numerous neurological therapies, including 12 FDA-approved drugs for multiple sclerosis since 2011, NeuroRx has proven its role as a valuable resource in the clinical research landscape.
Leadership Transition and Future Vision
Douglas Arnold, M.D., the founder and CEO of NeuroRx, is set to join Clario as a Senior Scientific Advisor. He notes, "Since our inception, we've been focused on leveraging imaging science to foster the development of groundbreaking treatments for neurological conditions. Joining Clario enables us to reach broader horizons and intensify our innovation." His extensive experience in overseeing over 300 clinical trials positions him as an invaluable asset to Clario.
A Deeper Commitment to Neuroscience
Clario's recent acquisition of NeuroRx coincides with another significant agreement to purchase WCG's eCOA business, reinforcing its scientific insights and enhancing delivery capabilities in neuroscience. Joyce Suhy, Ph.D., Clario's Executive Vice President, remarked on the profound challenges in the neuroscience field, underscoring the necessity of deep expertise and commitment to success.
Impact on Drug Development
The collaboration between Clario and NeuroRx aims to bolster advancements in drug development for neurological disorders. With the addition of NeuroRx’s capabilities, Clario is poised to enhance the development pathways for treatments targeting conditions such as Huntington's, Parkinson's, and Alzheimer's diseases.
About Clario
Clario is recognized as a leader in endpoint data solutions for the clinical trials sector, delivering high-quality clinical evidence for life sciences companies. With over 50 years of experience, Clario has been instrumental in supporting clinical trials in more than 100 countries, leveraging its wide array of technologies and scientific knowledge to aid in the approval of over 60% of FDA drugs since 2012.
About NeuroRx
NeuroRx, founded by Dr. Douglas Arnold in 2002, specializes in imaging solutions for diseases affecting the central nervous system. The company has a vast portfolio, having contributed to over 300 clinical trials across 82 countries, making it a prominent player in the landscape of neurological research.
Frequently Asked Questions
What recent acquisition did Clario announce?
Clario announced the acquisition of NeuroRx, enhancing its expertise in neuroscience and imaging capabilities.
What expertise does NeuroRx bring to Clario?
NeuroRx offers extensive imaging analysis services and has supported the approval of numerous neurological therapies.
Who is Douglas Arnold?
Douglas Arnold is the founder of NeuroRx and will join Clario as a Senior Scientific Advisor, bringing extensive experience in clinical trials.
Why is neuroscience a focus for Clario?
Neuroscience represents significant challenges and opportunities within medicine, highlighting the need for specialized expertise and commitment in drug development.
How does Clario support clinical trials?
Clario provides endpoint data solutions that generate high-quality clinical evidence, helping life sciences companies in their research and trials.
